Drug Profile
Research programme: influenza therapeutics - Alexander Biodiscoveries
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Alexander Biodiscoveries
- Class Antivirals; Small molecules
- Mechanism of Action Viral nonstructural protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA
- 11 Aug 2016 Preclinical trials in Influenza virus infections in USA (unspecified route)